Terry Plasse - RedHill Biopharma Medical Director
Director
Dr. Terry F. Plasse, M.D. is Medical Director of the Company. Dr. Plasse has extensive experience in drug development, primarily in oncology, having worked with several large as well as small pharmaceutical and biotech firms. He was previously Director for Oncology for North America at RhonePoulenc Rorer and served as a consultant to several major firms, including Chiron, Merck and BristolMyers Squibb since 2016.
| Tenure | 8 years |
| Phone | 972 3 541 3131 |
| Web | http://www.redhillbio.com |
RedHill Biopharma Management Efficiency
The company has return on total asset (ROA) of (32.82) % which means that it has lost $32.82 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (246.27) %, meaning that it generated substantial loss on money invested by shareholders. RedHill Biopharma's management efficiency ratios could be used to measure how well RedHill Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 85.89 M in total debt with debt to equity ratio (D/E) of 2.99, implying the company greatly relies on financing operations through barrowing. RedHill Biopharma has a current ratio of 1.76, which is within standard range for the sector. Debt can assist RedHill Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, RedHill Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like RedHill Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for RedHill to invest in growth at high rates of return. When we think about RedHill Biopharma's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Prahlad | Infosys Ltd ADR | 60 | |
| Susan Kilsby | Diageo PLC ADR | 62 | |
| Ramaswamy Seshasayee | Infosys Ltd ADR | 68 | |
| Nicola Mendelsohn | Diageo PLC ADR | 47 | |
| Melissa Bethell | Diageo PLC ADR | 46 | |
| Naamit Salomon | Sapiens International | 53 | |
| James Ellis | Willamette Valley Vineyards | 69 | |
| Kwon Ho | Diageo PLC ADR | 65 | |
| Sundaram | Infosys Ltd ADR | 64 | |
| John Etchemendy | Infosys Ltd ADR | 63 | |
| Charlotte Lambkin | Diageo PLC ADR | 43 | |
| Stanley Turel | Willamette Valley Vineyards | 66 | |
| Heather Westing | Willamette Valley Vineyards | N/A | |
| Ireena Vittal | Diageo PLC ADR | 51 | |
| U Rao | Infosys Ltd ADR | 58 | |
| Valerie ChapoulaudFloquet | Diageo PLC ADR | 58 | |
| Kathryn Mikells | Diageo PLC ADR | 54 | |
| Evan Davies | Diageo PLC ADR | 67 | |
| Christopher Sarles | Willamette Valley Vineyards | 49 | |
| Eyal BenChelouche | Sapiens International | 55 | |
| Alan Stewart | Diageo PLC ADR | 56 | |
Management Performance
| Return On Equity | -246.27 | |||
| Return On Asset | -32.82 |
RedHill Biopharma Leadership Team
Elected by the shareholders, the RedHill Biopharma's board of directors comprises two types of representatives: RedHill Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of RedHill. The board's role is to monitor RedHill Biopharma's management team and ensure that shareholders' interests are well served. RedHill Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, RedHill Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Patricia Anderson, Vice President - Regulatory Affairs | ||
| Micha Chorin, CFO | ||
| Ofer Tsimchi, Director | ||
| Patrick Mclean, Product Manager | ||
| Aida Bibliowicz, Vice President - Clinical Affairs Europe | ||
| Ori Shilo, Co-Founder and Deputy CEO of Fin. and Operations | ||
| Shmuel Cabilly, Director | ||
| Dror BenAsher, Chairman of the Board, CEO | ||
| Rob Jackson, Vice President of Marketing | ||
| Kenneth Reed, Director | ||
| Elkan Gamzu, Product Manager | ||
| Robert Gilkin, Vice President of Market Access | ||
| Adi Frish, Sr. VP of Bus. Devel. and Licensing | ||
| Steven Thomasian, Vice President of Supply Chain | ||
| Guy Goldberg, Chief Business Officer | ||
| Reza Fathi, Sr. VP of RandD | ||
| Tom Lang, Vice President - Regulatory & Clinical Affairs | ||
| Clara Fehrmann, Product Manager | ||
| Pascal Weerts, Director - Corporate and Legal Affairs | ||
| Eric Swenden, Director | ||
| Dan Suesskind, Director | ||
| Gilead Raday, Senior Vice President - Product and Corporate Development | ||
| Rick Scruggs, Director | ||
| Terry Plasse, Medical Director | ||
| Danielle Abramson, Director - Intellectual Property & Research | ||
| Uri Aharon, Chief Accounting Officer | ||
| Shani Maurice, Vice President - Business Development & Communications | ||
| Patricia Bandeira, Product Manager - Oncology | ||
| Ira Kalfus, Medical Director | ||
| Nurit Benjamini, External Director |
RedHill Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is RedHill Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -246.27 | |||
| Return On Asset | -32.82 | |||
| Profit Margin | (142.81) % | |||
| Operating Margin | (123.49) % | |||
| Current Valuation | 76.08 M | |||
| Shares Outstanding | 234.96 M | |||
| Shares Owned By Insiders | 4.94 % | |||
| Shares Owned By Institutions | 0.20 % | |||
| Price To Earning | (4.01) X | |||
| Price To Book | 0.87 X |
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in RedHill Pink Sheet
If you are still planning to invest in RedHill Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the RedHill Biopharma's history and understand the potential risks before investing.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |